Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A PHASE II STUDY OF CHEMOTHERAPY, MOZOBIL AND G-CSF AS MOBILIZING THERAPY FOR DOUBLE AUTOLOGOUS TRANSPLANTATION (ASCT) IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B CELL NON HODGKIN LYMPHOMA (DLBCL), PET POSITIVE AFTER TWO R-DHAP Studio di fase II per valutare l'efficacia e la sicurezza di chemioterapia, mozobil e G-CSF come terapia mobilizzante per doppio trapianto autologo (ASCT) in pazienti affetti da Linfoma Non Hodgkin diffuso a grandi cellule B (DLBCL) recidivato o refrattario, PET positivo dopo 2 cicli R-DHAP

Next Previous
Trial Profile

A PHASE II STUDY OF CHEMOTHERAPY, MOZOBIL AND G-CSF AS MOBILIZING THERAPY FOR DOUBLE AUTOLOGOUS TRANSPLANTATION (ASCT) IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B CELL NON HODGKIN LYMPHOMA (DLBCL), PET POSITIVE AFTER TWO R-DHAP Studio di fase II per valutare l'efficacia e la sicurezza di chemioterapia, mozobil e G-CSF come terapia mobilizzante per doppio trapianto autologo (ASCT) in pazienti affetti da Linfoma Non Hodgkin diffuso a grandi cellule B (DLBCL) recidivato o refrattario, PET positivo dopo 2 cicli R-DHAP

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Mar 2014

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Plerixafor (Primary)
  • Indications Stem cell mobilisation
  • Focus Therapeutic Use
  • Sponsors Sanofi Genzyme

    • Most Recent Events

    • 10 Mar 2014 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top